EasyJet is enduring a very challenging period. The low cost company flew a record 22 million passengers in the three months to Sept. 30, but revenue per seat fell by 8.7% from the same period last year, at constant currency as EasyJet has invested in pricing in order to boost passenger numbers. This included a strong load factor of 93.9%, with passengers benefitting from low fares across its network.
Abellio, british rail operator and swiss Stadler Rail announced on October 5 to have signed the agreement worth more than £600m (CHF 762 mln) to supply 378 multiple-unit cars for the next East Anglia franchise. In this way all existing trains on the Greater Anglia rail route will be replaced within the next four years.
Google has already been named as a potential bidder for Twitter, Bloomberg reported, citing "a person familiar with the arrangement," that Alphabet subsidiary Google is working with financial advisers Lazard to explore a bid for the social media company. Nonetheless, its spokeswoman Gina Scigliano refused to comment on the situation. A Lazard representative did not immediately respond to a request for comment.
Facebook announced on Monday it is launching Marketplace, its version of the local rummage sale. With its 1.71 billion users, it’s trying to capitalize on the e-commerce potential of its massive user base. According to company, more than 450 million people already visit Facebook groups that have items to buy and sell each month.
The new marketplace allows users to find things to buy from users nearby, list items quickly, and through Facebook messenger, users can communicate to negotiate deals and arrange a meet up.
US drug giant AstraZeneca said on Monday that it has signed a deal with Allergan through its global biologics research and development unit MedImmune, where the latter will pay up to $1.52B for rights to MEDI2070, an antibody for Crohn’s disease.
Allergan pays $250mln up front, but it might also make payments worth up to $1.27bln over a period of up to 15 years, tied to potential sales of the antibody, MEDI2070, a treatment that is currently undergoing clinical trials for moderate to severe Crohn’s disease.
The Swiss market mergers and acquisitions declined in Q3 2016. Compared to Q2, the number of transactions increased from 107 to 80 while the volume fell to $ 9.3 billion from 22.2 billion.
If compared with the same period last year, which had been strongly influenced by the $28.3 billion-deal, US Chubb’s acquisition by Zurich-based american insurer ACE, the volume of transactions fell by 32.2 billion, KPMG writes in a statement released yesterday.
For qualified investors / professional clients only
In order to proceed, you must confirm that you are a qualified investor based in Switzerland
The information contained in this section have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document.
Before investing in a product please read the latest prospectus carefully and thoroughly and note that funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided without any guarantee or warranty and are for the recipient's personal use and information purposes only